References

10.1016/s1470-2045(16)30123-1

10.1016/s1470-2045(16)30123-1 · External reference

10.3748/wjg.v23.i26.4675

10.3748/wjg.v23.i26.4675 · External reference

10.1056/nejm200104053441401

10.1056/nejm200104053441401 · External reference

10.1126/science.3798106

10.1126/science.3798106 · External reference

10.1056/nejm200103153441101

10.1056/nejm200103153441101 · External reference

10.1016/s1470-2045(16)00150-9

10.1016/s1470-2045(16)00150-9 · External reference

10.1016/s0140-6736(10)61121-x

10.1016/s0140-6736(10)61121-x · External reference

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers

10.1200/jco.2009.26.5983 · 2010 · External reference

10.1158/1078-0432.ccr-12-1627

10.1158/1078-0432.ccr-12-1627 · External reference

10.1158/1078-0432.ccr-14-0603

10.1158/1078-0432.ccr-14-0603 · External reference

10.1158/1535-7163.mct-15-0795

10.1158/1535-7163.mct-15-0795 · External reference

10.1158/0008-5472.can-15-3043

10.1158/0008-5472.can-15-3043 · External reference

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

10.1186/s13073-016-0364-2 · 2016 · External reference

Precision medicine: clinical outcomes including long-term survival according to the pathway targeted and treatment period–the IMPACT study

2018 · External reference

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

10.1016/s1470-2045(13)70611-9 · 2014 · External reference

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

10.1001/jama.2014.3741 · 2014 · External reference

10.1158/2159-8290.cd-16-1396

10.1158/2159-8290.cd-16-1396 · External reference

Unresolved reference

2017 · External reference

Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study

2018 · External reference

Integrative clinical sequencing in the Management of Refractory or relapsed Cancer in youth

10.1001/jama.2015.10080 · 2015 · External reference

10.18632/oncotarget.16057

10.18632/oncotarget.16057 · External reference

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project

10.18632/genesandcancer.121 · 2016 · External reference

WINTHER: an international WIN consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies

10.1200/jco.2018.36.15_suppl.12011 · 2018 · External reference

10.1093/annonc/mdv191

10.1093/annonc/mdv191 · External reference

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: results from the National Cancer Institute (NCI) molecular analysis for therapy choice (MATCH) trial

2018 · External reference

Molecular analysis for therapy choice (MATCH) arm W: phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway

2018 · External reference

Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors

2018 · External reference

NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein loss

10.1093/annonc/mdy279.406 · 2018 · External reference

Unresolved reference

External reference

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

10.1016/s1470-2045(15)00188-6 · 2015 · External reference

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

10.1093/annonc/mdw666 · 2017 · External reference

10.1200/jco.2015.61.5997

10.1200/jco.2015.61.5997 · External reference

Association of Biomarker-Based Treatment Strategies with Response Rates and Progression-Free Survival in refractory malignant neoplasms: a meta-analysis

10.1001/jamaoncol.2016.2129 · 2016 · External reference

1676PComparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: a pooled analysis from 4 contemporary prospective studies

2018 · External reference

Precision medicine: lessons learned from the SHIVA trial

10.1016/s1470-2045(15)00397-6 · 2015 · External reference

Precision medicine: lessons learned from the SHIVA trial

2015 · External reference

Precision medicine: lessons learned from the SHIVA trial

10.1016/s1470-2045(15)00387-3 · 2015 · External reference

10.1056/nejmoa1500596

10.1056/nejmoa1500596 · External reference

10.1373/clinchem.2014.222679

10.1373/clinchem.2014.222679 · External reference

10.1038/nrclinonc.2013.110

10.1038/nrclinonc.2013.110 · External reference

An overview of the NCI precision medicine trials-NCI MATCH and MPACT

2015 · External reference

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

10.1093/annonc/mdw223 · 2016 · External reference

Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine

10.14694/edbook_am.2013.33.118 · 2013 · External reference